Æó°íÇ÷¾Ð Ä¡·á ÆÐ·¯´ÙÀÓÀ» ¹Ù²Ù´Â ÁßÀç¼úÀÇ ´ë°¡
À强¾Æ ±³¼ö´Â Æó°íÇ÷¾Ð ºÐ¾ß¿¡¼ µ¶º¸ÀûÀÎ À§»óÀ» °¡Áø Àü¹®°¡ÀÌ´Ù. À强¾Æ ±³¼ö´Â Æó°íÇ÷¾Ð Ä¡·á¿¡ ÀÖ¾î ´ÙÇÐÁ¦Àû Á¢±ÙÀ» °Á¶ÇÑ´Ù. ¸¸¼º Æó»öÀüÁõ¼º Æó°íÇ÷¾Ð°ú °°Àº °í³µµ ÁúȯÀÇ Ä¡·á¿¡ ¼ö¼ú°ú ½Ã¼úÀ» °áÇÕÇÏ¿© ÃÖÀûÀÇ °á°ú¸¦ µµÃâÇÏ´Â µ¥ ÁßÁ¡À» µÎ°í ÀÖ´Ù. ƯÈ÷, Áø´ÜÀÌ ¾î·Æ°í Ä¡·á °úÁ¤ÀÌ º¹ÀâÇÑ Æó°íÇ÷¾Ð ȯÀÚµéÀ» À§ÇØ ÃֽŠÁö°ßÀ» ¹ÙÅÁÀ¸·Î ÇÑ ¸ÂÃãÇü Ä¡·á Àü·«À» Á¦½ÃÇϸç, ±¹³»¿Ü ÇÐȸ Ȱµ¿À» ÅëÇØ Æó°íÇ÷¾Ð Áø·áÀÇ Ç¥ÁØÀ» ³ôÀÌ´Â µ¥ ±â¿©Çϰí ÀÖ´Ù. Æó°íÇ÷¾Ð ȯÀÚµéÀÇ »ýÁ¸À² Çâ»ó°ú »îÀÇ Áú °³¼±À» À§ÇØ Çå½ÅÇÏ´Â Çϰí ÀÖ´Ù.
| Á¦ ¸ñ | Recent Advances in Chronic Thromboembolic Pulmonary Hypertension: Expanding the Disease Concept and Treatment Options | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2025 | ¹ßÇ¥Áö | Korean Circulation Journal |
| Á¦ ¸ñ | Programmed Follow-up and Quality Control of Treatment Techniques Enhance Chronic Thromboembolic Pulmonary Hypertension Management: Lessons From a Multidisciplinary Team | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2024 | ¹ßÇ¥Áö | Korean Circulation Journal |
| Á¦ ¸ñ | A Single Center Experience of Pulmonary Arterial Hypertension Management in Korea: A 25-Year Comparative Analysis Following the Introduction of Targeted Therapy | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2024 | ¹ßÇ¥Áö | Korean Circulation Journal |
| Á¦ ¸ñ | Endovascular Treatment for Peripheral Pulmonary Arterial Stenosis in RNF213-Related Vasculopathy | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2024 | ¹ßÇ¥Áö | Journal of Vascular and Interventional Radiology |
| Á¦ ¸ñ | Pattern of pericardial calcification determines mid-term postoperative outcomes after pericardiectomy in chronic constrictive pericarditis | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2023 | ¹ßÇ¥Áö | International Journal of Cardiology |
| Á¦ ¸ñ | Clinical Course of Suspected Diagnosis of Pulmonary Tumor Thrombotic Microangiopathy: A 10-Year Experience of Rapid Progressive Right Ventricular Failure Syndrome in Advanced Cancer Patients | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2023 | ¹ßÇ¥Áö | Korean Circulation Journal |
| Á¦ ¸ñ | Safety and effectiveness of ambrisentan in real clinical practice in pulmonary arterial hypertension: Results from the Korean post-marketing surveillance | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2023 | ¹ßÇ¥Áö | Pharmacoepidemiology and Drug Safety |

»ï¼º¼¿ïº´¿øÀº 1994³â °³¿øÇÑ Á¾ÇÕ ÀÇ·á±â°üÀ¸·Î º»°ü, º°°ü, ¾Ïº´µ¿À¸·Î ±¸¼ºµÅ ÀÖÀ¸¸ç ¾à 1979º´»ó ±Ô¸ð¸¦ °®Ãß°í ÀÖ´Ù. 2014³â ¾ç¼ºÀÚ Ä¡·á¼¾ÅÍ, 2015³â ¹Ì·¡ ÀÇÇаüÀÌ ¿Ï°øµÆÀ¸¸ç, ÇöÀç 2019³â ¿Ï°øÀ» ¸ñÇ¥·Î Åë¿øÄ¡·á¼¾ÅÍ °ø»ç¸¦ ÁøÇàÇϰí ÀÖ´Ù. ȯÀÚ ÇູÀ» À§ÇÑ ÀÇ·á Çõ½Å ±¸Çö, º´¿ø-¿¬±¸¼Ò-Çб³-±â¾÷ü¸¦ ¿¬°áÇÏ´Â ¹ÙÀÌ¿À ÇコÄÉ¾î ¿¬±¸ ¹× ¿¬°è »ê¾÷ÀÇ ±Û·Î¹ú Çãºê¸¦ ¸ñÇ¥·Î ÇÑ´Ù.
¼¿ïƯº°½Ã °³²±¸ ÀÏ¿ø·Î 81